Brief: Chosa Oncology Presents Clinical Phase 2 Results Of Liplacis And Its Drug Response Predictor Test
25/05/2023 22:04
May 25 (Reuters) - Chosa Oncology AB CHOSA.TE :
* CHOSA ONCOLOGY AB PRESENTS CLINICAL PHASE 2 RESULTS OF
LIPLACIS
AND ITS DRUG RESPONSE PREDICTOR TEST AT ASCO 2023
* CHOSA - RESULTS SHOW THAT PATIENTS WHO GET HIGH SCORES IN
DRP
READING ARE ONLY ONES THAT RESPOND AND SHOW 2.5X LONGER MEDIAN
PFS
Source text for Eikon: ID:nWkr64G02Z
Further company coverage: CHOSA.TE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chosa Oncology AB
See all newsBrief: Chosa Oncology Appoints Gerton Jönsson As New Chief Financial Officer
Brief: CHOSA Oncology AB Says Postpones Publication Of Interim Report Q4 2024
Brief: Chosa Oncology Carried Out Directed Issue Of Sek 1,55 Mln To Further Increase Business Development Activities
Brief: Chosa Oncology Announces Decision To Postpone Release Of Interim Report For Q2 2023
Brief: Chosa Oncology AB Publishes Results From Clinical Phase 2 Trial Of Liposomal Formulation In Breast Cancer, Using Predictive Marker For Cisplatin